3/26
04:05 pm
osa
ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results
Low
Report
ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results
3/15
08:01 pm
osa
ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call
Low
Report
ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call
2/22
08:30 am
osa
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
Medium
Report
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
2/20
04:05 pm
osa
ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024
High
Report
ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024
1/30
08:00 am
osa
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
Medium
Report
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
1/29
08:00 am
osa
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
Low
Report
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
1/22
03:46 pm
osa
ProSomnus, Inc. (NASDAQ: OSA) is now covered by analysts at Alliance Global Partners. They set a "buy" rating and a $2.00 price target on the stock.
Low
Report
ProSomnus, Inc. (NASDAQ: OSA) is now covered by analysts at Alliance Global Partners. They set a "buy" rating and a $2.00 price target on the stock.